Cancer Gene Therapy Market Size, Share, Growth, and Industry Analysis, By Type (Oncolytic Virotherapy,Gene Transfer,Gene-Induced Immunotherapy), By Application (Hospitals,Diagnostics Centers,Research Institutes), Regional Insights and Forecast to 2035

Cancer Gene Therapy Market Overview

The global Cancer Gene Therapy Market size is projected to grow from USD 853.31 million in 2026 to USD 1005.2 million in 2027, reaching USD 3760.39 million by 2035, expanding at a CAGR of 17.8% during the forecast period.

In 2024, the global Cancer Gene Therapy Market was valued at approximately USD 4.51 billion, with projections indicating a value near USD 4.14 billion in 2025. Forecasts suggest the market could reach nearly USD 12.76 billion by 2030, reflecting a major expansion driven by advanced oncology research and clinical adoption. Viral vectors remain the leading platform, utilized in over 70% of all cancer gene therapy candidates globally. In Q1 2025, about 57% of new gene therapy clinical trials were initiated for oncology indications, highlighting oncology’s dominance within the gene therapy field. Since 1986, over 5,600 interventional cancer cell therapy trials have been registered worldwide, showing sustained clinical activity and technology maturation. This foundation drives the Cancer Gene Therapy Market Report, Cancer Gene Therapy Market Trends, and overall Cancer Gene Therapy Market Outlook.

The U.S. Cancer Gene Therapy Market reached approximately USD 2.13 billion in 2024, up from an estimated USD 1.25 billion in 2023. The U.S. accounts for roughly 67% of all global gene therapy trials historically conducted, making it the central hub of innovation. Strong regulatory oversight, advanced clinical infrastructure, and concentrated biotech investment have positioned the United States as a global leader. U.S. oncology centers perform hundreds of active clinical gene therapy trials annually, supported by FDA frameworks and academic-industry partnerships. The U.S. remains pivotal in global Cancer Gene Therapy Market Share and serves as a commercialization anchor for upcoming therapeutic launches.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 57% of new gene therapy trials initiated in Q1 2025 targeted oncology, highlighting oncology’s continued dominance.
• Major Market Restraint: Approximately 95% of gene therapy trials remain in early clinical stages, limiting commercial outputs.
• Emerging Trends: Around 51% of newly initiated gene therapy programs now address non-oncology indications, showing diversification.
• Regional Leadership: North America holds more than 50% of global cell and gene therapy activities.
• Competitive Landscape: The top two companies collectively control about 25–30% of the global oncology gene therapy pipeline.
• Market Segmentation: Viral vector-based therapies represent over 70% of all cancer gene therapy platforms.
• Recent Development: In Q1 2025, 79 new gene therapy trials were launched globally, with 57% dedicated to cancer treatment.

Cancer Gene Therapy Market Latest Trends

Recent Cancer Gene Therapy Market Trends indicate growing integration of genetic modification technologies with oncology therapeutics. In 2025, 57% of new gene therapy trials targeted cancer, confirming oncology’s status as the principal therapeutic area. Viral vector platforms dominate over 70% of projects, while non-viral systems such as nanoparticle and mRNA vectors account for 25–30% of newer developments. The share of non-oncology programs has also grown to 51%, reflecting diversification across rare diseases. Immunogene therapy, particularly CAR T-cell and gene-modified NK cell products, now constitute a major segment of clinical pipelines. The U.S. remains the largest market, exceeding USD 2.13 billion in value, supported by more than 67% of global trial activity. Globally, over 5,600 interventional cancer cell therapy trials have been registered, underscoring robust research activity. Industry focus is shifting toward scalable vector manufacturing and modular platform technologies. Developers are working on standardization, regulatory harmonization, and accelerated production cycles. These trends emphasize oncology’s enduring leadership while extending opportunities into precision diagnostics, companion biomarker testing, and personalized gene therapy solutions, forming the core of Cancer Gene Therapy Market Insights and forward growth strategy.

Cancer Gene Therapy Market Dynamics

DRIVER

" Rising global cancer incidence and therapeutic demand"

The global cancer incidence exceeded 19.3 million new cases in 2020, with mortality surpassing 9.9 million deaths annually. This high burden fuels demand for advanced genetic interventions that target resistant malignancies. Gene therapy introduces or edits genes to correct tumor progression mechanisms. Around 30–40% of oncology programs now combine gene therapy with immune checkpoint inhibitors. Strong governmental and venture funding supports the rising R&D pipeline, especially in the United States and Europe. Investment focus has shifted toward modular vector systems that enable faster clinical transitions, solidifying cancer gene therapy as one of the fastest-evolving therapeutic domains in biopharma.

RESTRAINT

" Clinical risk, regulatory complexity, and limited approvals"

Despite rising clinical interest, 95% of all gene therapy trials remain in early development stages, limiting approved therapies. Regulatory requirements mandate long-term follow-up and post-treatment safety verification, extending approval timelines. Viral vector supply shortages affect about 25% of active programs globally. Manufacturing reproducibility, immunogenicity, and insertional mutagenesis risks hinder rapid clinical scaling. The high cost of therapy—often exceeding USD 500,000 per patient—further restricts access. These barriers slow the transition from research to commercial viability and impact global Cancer Gene Therapy Market Growth momentum.

OPPORTUNITY

" Personalized therapies, modular vectors, and strategic partnerships"

Advances in modular gene therapy platforms create opportunities for customizable and scalable oncology treatments. Plug-and-play vector backbones reduce development cycles, allowing payload modifications for different tumor types. The growing global CDMO market for gene therapy manufacturing exceeded USD 3.19 billion in 2024, boosting production capacity. Biotech–pharma partnerships continue to expand; joint ventures accelerate commercialization and reduce regulatory risk. The oncology focus in gene therapy allows premium pricing in rare and refractory cancers. Emerging regions like Asia-Pacific are also investing in gene therapy innovation hubs, further expanding the opportunity landscape for global collaboration and licensing.

CHALLENGE

" Cost, reimbursement, and commercialization hurdles"

Cancer gene therapy faces significant economic and operational challenges. Single-dose treatments can cost upwards of USD 1 million, making payer adoption difficult. Global reimbursement frameworks vary widely and often lack standardization. Supply chain requirements for viral vectors demand ultra-cold storage and precise logistics. Patient populations for certain cancers remain small, limiting scalability. Regulatory complexities and cross-border trial discrepancies add to development delays. Physician education and patient access to specialized centers remain ongoing obstacles. Addressing cost, reimbursement, and access will be essential for sustaining long-term Cancer Gene Therapy Market Expansion and patient impact.

Cancer Gene Therapy Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Oncolytic Virotherapy: Oncolytic virotherapy uses engineered viruses to selectively infect and lyse tumor cells. These therapies account for roughly 15–25% of all oncology gene therapy programs. Late-stage clinical trials target melanoma, glioblastoma, and gastrointestinal cancers. Approximately 30% of oncolytic trials combine virotherapy with checkpoint inhibitors, enhancing immune responses. The segment benefits from shared vector technology with gene transfer platforms and holds growing regulatory acceptance. Dual-function oncolytic vectors (viral kill + gene payload) define a key frontier in Cancer Gene Therapy Market Trends.

The Oncolytic Virotherapy segment is projected to reach USD 289.41 million in 2025, accounting for 39.9% market share, and expected to touch USD 1258.84 million by 2034, growing at a CAGR of 17.6%.

Top 5 Major Dominant Countries in the Oncolytic Virotherapy Segment:

• United States: Expected at USD 132.65 million in 2025 with 45.8% share, projected to reach USD 578.73 million by 2034, registering a CAGR of 17.9% due to high clinical adoption and trial success.
• Germany: Valued at USD 41.92 million in 2025 with 14.5% share, forecasted to achieve USD 188.14 million by 2034, growing at a CAGR of 17.7% supported by regulatory ease in gene therapy trials.
• China: Estimated at USD 36.47 million in 2025 with 12.6% share, expected to reach USD 165.32 million by 2034 at a CAGR of 17.8%, driven by increased cancer prevalence and biotech innovation.
• Japan: Stands at USD 29.65 million in 2025 with 10.2% share, projected to grow to USD 134.51 million by 2034 with a CAGR of 17.9%, influenced by strong clinical infrastructure.
• United Kingdom: Records USD 24.21 million in 2025 with 8.4% share, expected to reach USD 109.52 million by 2034, at a CAGR of 17.7% backed by expanding biotech investments.

Gene Transfer: Gene transfer therapy remains the backbone of cancer gene therapy, representing over half of all active programs. These therapies deliver corrective or cytotoxic genes such as p53, PTEN, or HSV-TK into tumor cells. Viral vectors dominate this category, accounting for more than 70% of total applications. Non-viral plasmid and nanoparticle-based systems account for about 20% of newer pipelines. The versatility of gene transfer makes it central in both monotherapy and adjunctive approaches with chemotherapy or radiation. It underpins most late-stage developments and drives overall Cancer Gene Therapy Market Share.

The Gene Transfer segment is valued at USD 266.29 million in 2025, holding 36.8% market share, and anticipated to reach USD 1168.92 million by 2034, exhibiting a CAGR of 17.9%.

Top 5 Major Dominant Countries in the Gene Transfer Segment:

• United States: Valued at USD 122.55 million in 2025 with 46% share, reaching USD 544.96 million by 2034 with a CAGR of 17.8% due to advanced vector technology.
• China: Estimated at USD 40.71 million in 2025 with 15.3% share, projected to attain USD 182.79 million by 2034, growing at 17.9% CAGR supported by government oncology programs.
• Germany: Worth USD 33.28 million in 2025 with 12.5% share, expected to grow to USD 149.62 million by 2034, at a CAGR of 17.8% from increased R&D collaborations.
• Japan: Reaches USD 26.19 million in 2025 with 9.8% share, forecasted to expand to USD 117.74 million by 2034 at a CAGR of 17.7%, propelled by hospital-based adoption.
• France: Holds USD 22.76 million in 2025 with 8.5% share, reaching USD 102.34 million by 2034 at a CAGR of 17.6%, benefiting from active biotech sector growth.

Gene-Induced Immunotherapy: Gene-induced immunotherapy integrates immune activation through genetic modification, forming one of the most active subfields. Around 57% of ongoing gene therapy trials target oncology, many being CAR T or TCR gene-modified immune cells. Over 5,600 cancer cell therapy trials have been conducted globally, underscoring maturity. The segment shows high efficacy in hematological malignancies and emerging application in solid tumors. This convergence of immunotherapy and genetic engineering defines future expansion of the Cancer Gene Therapy Market Outlook.

The Gene-Induced Immunotherapy segment is forecasted to be valued at USD 168.67 million in 2025 with a 23.3% share, reaching USD 764.42 million by 2034 at a CAGR of 17.9%.

Top 5 Major Dominant Countries in the Gene-Induced Immunotherapy Segment:

• United States: Estimated at USD 80.11 million in 2025 with 47.5% share, likely to reach USD 362.23 million by 2034, showing 18.0% CAGR owing to rapid CAR-T advancements.
• Germany: Valued at USD 27.39 million in 2025 with 16.2% share, projected to hit USD 123.91 million by 2034, growing at a CAGR of 17.8% due to high immunotherapy investments.
• Japan: At USD 22.57 million in 2025 with 13.4% share, reaching USD 101.93 million by 2034, growing at 17.8% CAGR driven by national cancer centers and R&D.
• China: Accounts for USD 20.24 million in 2025 with 12% share, set to achieve USD 91.36 million by 2034, at a CAGR of 17.9%, due to increasing biotech licensing.
• South Korea: Holds USD 18.36 million in 2025 with 10.9% share, expected to reach USD 85.72 million by 2034 at 17.9% CAGR due to strategic partnerships in gene immunotherapy.

BY APPLICATION

Hospitals: Hospitals conduct most clinical and commercial gene therapy administrations. Leading oncology centers treat hundreds of patients annually using approved or experimental therapies. Hospitals manage infusion, monitoring, and follow-up within certified gene therapy units. Over 60% of late-phase trials operate within hospital environments. Partnerships between hospitals and biopharma firms underpin commercialization. Hospitals remain central to treatment execution, post-approval surveillance, and data generation for Cancer Gene Therapy Market Insights.

Hospitals segment is estimated at USD 379.47 million in 2025, capturing 52.4% share, and forecasted to reach USD 1667.18 million by 2034, with a CAGR of 17.8%.

Top 5 Major Dominant Countries in the Hospitals Application:

• United States: Valued at USD 175.56 million in 2025 with 46.2% share, expected to reach USD 772.33 million by 2034, showing 17.9% CAGR due to hospital-centric cancer therapies.
• Germany: Estimated at USD 51.92 million in 2025 with 13.7% share, reaching USD 228.37 million by 2034 at a 17.8% CAGR supported by strong oncology treatment networks.
• Japan: Stands at USD 43.38 million in 2025 with 11.4% share, projected to touch USD 190.99 million by 2034 at 17.8% CAGR, with steady clinical adoption growth.
• China: At USD 39.14 million in 2025 with 10.3% share, expected to reach USD 171.69 million by 2034 with 17.9% CAGR due to high hospitalization rates.
• France: Records USD 32.75 million in 2025 with 8.6% share, reaching USD 143.80 million by 2034 at a CAGR of 17.8% from improved oncology care infrastructure.

Diagnostic Centers: Diagnostic and molecular testing centers play an enabling role by handling genomic screening, biomarker analysis, and eligibility assessments. They process tens of thousands of genomic profiles annually to identify patients suitable for gene therapy. Diagnostic collaborations are vital for patient selection, assay validation, and clinical monitoring. This infrastructure supports the integration of companion diagnostics, a critical success factor in precision oncology and Cancer Gene Therapy Market Forecast development.

Diagnostics Centers segment holds USD 205.86 million in 2025, capturing 28.4% share, and is projected to reach USD 906.78 million by 2034, with a CAGR of 17.9%.

Top 5 Major Dominant Countries in the Diagnostics Centers Application:

• United States: Accounts for USD 93.46 million in 2025 with 45.4% share, forecasted to reach USD 413.64 million by 2034, growing at 17.9% CAGR from precision diagnostic integration.
• Germany: Estimated at USD 30.47 million in 2025 with 14.8% share, likely to reach USD 135.57 million by 2034, growing at 17.8% CAGR from advanced gene-based testing.
• China: Stands at USD 27.81 million in 2025 with 13.5% share, projected to reach USD 122.55 million by 2034 at a CAGR of 17.9%, driven by rapid clinical lab expansion.
• Japan: Valued at USD 24.12 million in 2025 with 11.7% share, expected to reach USD 106.33 million by 2034 at 17.8% CAGR through growth in diagnostic imaging support.
• France: Holds USD 19.28 million in 2025 with 9.4% share, reaching USD 85.78 million by 2034 at 17.7% CAGR from strong public cancer screening programs.

Research Institutes: Academic and research institutions form the foundation of discovery and translational innovation. The U.S. leads with approximately 67% of global historical gene therapy trial origins. In Q1 2025 alone, 79 new gene therapy trials began, most involving research institute partnerships. Institutes manage early vector development, preclinical evaluation, and first-in-human studies. Their work feeds into commercial pipelines, establishing a critical bridge between science and application across the Cancer Gene Therapy Industry.

Research Institutes segment is valued at USD 139.04 million in 2025, accounting for 19.2% share, expected to reach USD 618.22 million by 2034 with a CAGR of 17.9%.

Top 5 Major Dominant Countries in the Research Institutes Application:

• United States: Estimated at USD 62.81 million in 2025 with 45.2% share, reaching USD 278.42 million by 2034 at 17.9% CAGR, propelled by ongoing gene therapy trials.
• Germany: Valued at USD 21.92 million in 2025 with 15.7% share, expected to achieve USD 97.18 million by 2034, with a CAGR of 17.8% supported by robust R&D initiatives.
• China: Holds USD 18.64 million in 2025 with 13.4% share, forecasted to touch USD 82.65 million by 2034, growing at 17.9% CAGR backed by genomic research expansion.
• Japan: Accounts for USD 17.27 million in 2025 with 12.4% share, likely to reach USD 76.54 million by 2034, showing 17.8% CAGR due to university-level research funding.
• South Korea: Stands at USD 14.40 million in 2025 with 10.3% share, projected to grow to USD 63.43 million by 2034, at 17.9% CAGR from new academic research programs.

Cancer Gene Therapy Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads globally, accounting for more than 50% of total cell and gene therapy activity. The U.S. Cancer Gene Therapy Market is valued at around USD 2.13 billion in 2024, hosting 67% of historical trial activity. Regulatory clarity, established vector manufacturing, and reimbursement readiness sustain leadership. Canada contributes through collaborative academic research and early-stage trial networks. High venture investment and robust CDMO infrastructure reinforce North America’s centrality in commercial scaling and innovation for gene-based oncology.

The North America Cancer Gene Therapy Market is valued at USD 312.23 million in 2025, representing 43.1% global share, projected to reach USD 1366.89 million by 2034 at a CAGR of 17.8%.

North America - Major Dominant Countries in the Cancer Gene Therapy Market:

• United States: USD 275.04 million in 2025 with 88.1% share, reaching USD 1204.24 million by 2034, growing at 17.9% CAGR from expanding oncology clinical base.
• Canada: USD 19.87 million in 2025 with 6.4% share, projected to reach USD 86.96 million by 2034 at 17.8% CAGR through active R&D programs.
• Mexico: USD 8.35 million in 2025 with 2.7% share, reaching USD 36.52 million by 2034, growing at 17.7% CAGR due to emerging medical infrastructure.
• Cuba: USD 5.49 million in 2025 with 1.8% share, forecasted to reach USD 24.09 million by 2034, expanding at 17.9% CAGR due to biopharma initiatives.
• Panama: USD 3.48 million in 2025 with 1.1% share, projected to reach USD 16.08 million by 2034 at 17.9% CAGR driven by regional medical adoption.

EUROPE

Europe ranks second globally with mature biotech ecosystems in Germany, France, the U.K., and Switzerland. Regional clinical activity includes hundreds of ongoing oncology gene therapy trials. EU regulatory harmonization under ATMP frameworks simplifies multinational studies. Reimbursement models vary, with some nations requiring long-term cost-effectiveness data. Europe’s strong academic-industrial collaboration supports advanced vector development and pan-European trial networks. This combination of regulatory sophistication and research excellence cements Europe’s significance in global Cancer Gene Therapy Market Growth.

The Europe Cancer Gene Therapy Market is forecasted at USD 202.93 million in 2025, holding 28.0% share, and expected to reach USD 888.14 million by 2034 with a CAGR of 17.8%.

Europe - Major Dominant Countries in the Cancer Gene Therapy Market:

• Germany: USD 61.78 million in 2025 with 30.4% share, reaching USD 270.23 million by 2034, growing at 17.8% CAGR due to robust biotech funding.
• United Kingdom: USD 46.65 million in 2025 with 23% share, reaching USD 204.01 million by 2034, at 17.9% CAGR supported by precision oncology investments.
• France: USD 36.47 million in 2025 with 18% share, reaching USD 159.65 million by 2034, growing at 17.8% CAGR from active clinical approvals.
• Italy: USD 30.32 million in 2025 with 15% share, expected to achieve USD 133.42 million by 2034 at 17.7% CAGR from institutional R&D growth.
• Spain: USD 27.71 million in 2025 with 13.6% share, reaching USD 120.83 million by 2034 at 17.8% CAGR from gene therapy adoption in public hospitals.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing region, with China, Japan, and South Korea leading. Trial activity has risen more than 30% since 2021. China and Japan are establishing domestic approval systems and scaling viral vector manufacturing. Localized production reduces import dependency and cost by 15–20%. Partnerships between Western and Asian biotech companies are expanding pipeline diversity. Asia’s rising cancer incidence and improving infrastructure position it as a high-growth region in Cancer Gene Therapy Market Opportunities.

The Asia Cancer Gene Therapy Market is projected at USD 145.69 million in 2025 with a 20.1% share, expected to reach USD 635.28 million by 2034, growing at a CAGR of 17.9%.

Asia - Major Dominant Countries in the Cancer Gene Therapy Market:

• China: USD 64.28 million in 2025 with 44.1% share, projected to reach USD 279.19 million by 2034 with 17.9% CAGR through large-scale biotech programs.
• Japan: USD 43.25 million in 2025 with 29.7% share, reaching USD 187.88 million by 2034, growing at 17.8% CAGR from healthcare infrastructure expansion.
• India: USD 19.87 million in 2025 with 13.6% share, forecasted to hit USD 86.31 million by 2034, at 17.9% CAGR from growing oncology demand.
• South Korea: USD 11.64 million in 2025 with 8% share, expected to reach USD 50.53 million by 2034 at 17.9% CAGR, with rising R&D partnerships.
• Singapore: USD 6.65 million in 2025 with 4.6% share, reaching USD 31.37 million by 2034 at 17.8% CAGR from clinical innovation programs.

MIDDLE EAST & AFRICA

The Middle East & Africa remain emerging regions, contributing a smaller share but increasing strategic significance. Gulf nations like Saudi Arabia and the UAE are establishing gene therapy programs and biotech parks. Clinical trials remain limited but collaborative. Cost, infrastructure, and regulatory limitations persist. However, growing cancer prevalence and government-led innovation initiatives drive gradual adoption. Africa’s early clinical trials and import partnerships lay the groundwork for future market participation.

The Middle East and Africa Cancer Gene Therapy Market is expected to be valued at USD 63.52 million in 2025 with 8.8% share, reaching USD 282.87 million by 2034, growing at 17.8% CAGR.

Middle East and Africa - Major Dominant Countries in the Cancer Gene Therapy Market:

• United Arab Emirates: USD 14.39 million in 2025 with 22.6% share, reaching USD 64.23 million by 2034 at 17.9% CAGR driven by biotechnology adoption.
• Saudi Arabia: USD 13.23 million in 2025 with 20.8% share, projected to touch USD 59.31 million by 2034 with 17.8% CAGR through growing cancer treatment programs.
• South Africa: USD 11.37 million in 2025 with 17.9% share, expected to achieve USD 51.00 million by 2034 with 17.8% CAGR supported by hospital network development.
• Egypt: USD 9.24 million in 2025 with 14.5% share, forecasted to reach USD 41.39 million by 2034, at 17.8% CAGR from increasing oncology R&D activities.
• Israel: USD 8.47 million in 2025 with 13.3% share, reaching USD 37.86 million by 2034, at 17.8% CAGR due to strong biotech research framework.

List of Top Cancer Gene Therapy Companies

• Adaptimmune
• Bluebird bio
• Celgene
• Shanghai Sunway Biotech
• Shenzhen SiBiono GeneTech
• SynerGene Therapeutics
• Altor BioScience
• Amgen
• Argenx
• BioCancell
• GlaxoSmithKline
• Merck
• OncoGenex Pharmaceuticals
• Transgene

Top Two Companies with the Highest Share

Bluebird bio: Holds approximately 15% global share across oncology-related gene therapy pipelines, with leading products in hematologic and solid tumor indications. Adaptimmune: Commands roughly 10% share, specializing in T-cell receptor and gene-engineered immunotherapies, maintaining strong trial progression and pharma partnerships.

Investment Analysis and Opportunities

The Cancer Gene Therapy Market attracts expanding venture and institutional investment driven by unmet clinical need and transformative potential. Global spending on cell and gene therapies rose 38% in 2023 to reach USD 5.9 billion. Oncology remains the highest-funded domain, with 57% of newly initiated trials in Q1 2025 dedicated to cancer. The global gene therapy CDMO sector achieved USD 3.19 billion in 2024, reinforcing infrastructure capacity. Investment flows increasingly target modular and scalable vector manufacturing, enabling multi-indication applications. Cross-border partnerships between academia and biotech reduce development risk and accelerate regulatory approvals.

New Product Development

Product innovation in cancer gene therapy is advancing toward multifunctional, safe, and scalable therapies. In 2025, new clinical entries featuring CRISPR/Cas and base editing technologies are expanding precision gene correction applications. Oncolytic virus candidates now include immune-modulatory payloads such as cytokine or checkpoint inhibitor genes. Roughly 25% of newer programs employ non-viral systems like nanoparticles or mRNA-based vectors. CAR T and TCR gene-induced immunotherapies dominate late-stage pipelines, with embedded safety mechanisms such as suicide switches or inducible expression systems.

Five Recent Developments

• In Q1 2025, 79 new gene therapy clinical trials were initiated globally, 57% of which targeted oncology.
• As of 2024, over 5,600 interventional cancer cell therapy trials have been registered worldwide.
• The global Cancer Gene Therapy Market reached approximately USD 4.51 billion in 2024.
• The U.S. Cancer Gene Therapy segment achieved USD 2.13 billion valuation within the North American region in 2024.
• Around 95% of global gene therapy trials remain in early clinical phases, reinforcing ongoing innovation.

Report Coverage of Cancer Gene Therapy Market

The Cancer Gene Therapy Market Report provides comprehensive global, regional, and national-level insights, analyzing market size, share, trends, and technology evolution. Segmentation includes Type (Oncolytic Virotherapy, Gene Transfer, Gene-Induced Immunotherapy) and Application (Hospitals, Diagnostic Centers, Research Institutes). Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa with detailed market analysis. Competitive profiling highlights major companies like Bluebird bio, Adaptimmune, Celgene, and Amgen, comparing pipelines, partnerships, and innovation strategies. Supporting modules cover Market Dynamics, Investment Insights, New Product Development, and Emerging Trends. The study integrates quantitative data from 2018–2024 with forecasts to 2030. It targets B2B stakeholders, including biopharma firms, investors, and healthcare strategists, offering actionable intelligence for decision-making. The report forms a foundation for understanding Cancer Gene Therapy Market Growth, Market Forecast, and future commercialization prospects. 

Cancer Gene Therapy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 853.31 Billion in 2026
Market Size Value By	USD 3760.39 Billion by 2035
Growth Rate	CAGR of 17.8% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Oncolytic Virotherapy Gene Transfer Gene-Induced Immunotherapy By Application : Hospitals Diagnostics Centers Research Institutes
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample